Ligand Pharmaceuticals Incorpor (LGND) Financials

LGND Assets vs Liabilities

DateAssetsLiabilities
2023-12-31 833.1 million 130.7 million
2023-09-30 769.2 million 103.8 million
2023-06-30 758.1 million 93.2 million
2023-03-31 811.1 million 164.8 million

LGND Free Cash Flow and Stock based compensation

Graph available only for supporters. Become a supporter to see it.
DateFree Cash FlowStock based compensation
2023-12-31 -42.7 million 5.7 million
2023-09-30 7.2 million 6.9 million
2023-06-30 -285000 7.2 million
2023-03-31 31.5 million 5.9 million

LGND Net Income

Graph available only for supporters. Become a supporter to see it.
DateNet Income
2023-12-31 18.2 million
2023-09-30 -10.3 million
2023-06-30 2.3 million
2023-03-31 41.9 million

LGND Cash and Debt

Graph available only for supporters. Become a supporter to see it.
DateCashDebtCapital Lease
2023-12-31 170.3 million - 6.2 million
2023-09-30 190.5 million - 6.3 million
2023-06-30 219.0 million - 11.7 million
2023-03-31 282.7 million - 11.9 million

LGND Shares Outstanding

Graph available only for supporters. Become a supporter to see it.
DateShares Outstanding
2023-12-31 17.7 million
2023-09-30 17.4 million
2023-06-30 17.7 million
2023-03-31 18.0 million

LGND Expenses

Graph available only for supporters. Become a supporter to see it.
DateCapexR&DG&AS&M
2023-12-31 50.7 million 5.5 million 16.0 million -
2023-09-30 487000 5.5 million 14.7 million -
2023-06-30 203000 6.9 million 11.3 million -
2023-03-31 2.4 million 6.7 million 10.9 million -

LGND Cost of Revenue

Graph available only for supporters. Become a supporter to see it.
DateRevenueCost of Revenue
2023-12-31 28.1 million 1.7 million
2023-09-30 32.9 million 3.5 million
2023-06-30 26.4 million 1.7 million
2023-03-31 44.0 million 3.7 million

LGND

Price: $73.90

52 week price:
49.24
94.57

Earnings Per Share: 3.03 USD

P/E Ratio: 65.36

Exchange: NGM

Sector: Healthcare

Industry: Biotechnology

Volume: 186100

Ebitda: 19.2 million

Market Capitalization: 1.4 billion

Links: